What is the contraceptive failure rate of depot medroxyprogesterone acetate (Depo‑Provera)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Depo-Provera Contraceptive Failure Rate

Depo-Provera (depot medroxyprogesterone acetate) has a typical use failure rate of 6% and a perfect use failure rate of 0.2-0.3%, making it 94% effective with typical use but over 99% effective with perfect adherence to the 12-week injection schedule. 1

Failure Rate Data by Use Pattern

The distinction between typical and perfect use is critical for understanding Depo-Provera's real-world effectiveness:

  • Typical use failure rate: 6% - This reflects actual pregnancy rates when women may miss or delay appointments for their quarterly injections 1, 2, 3
  • Perfect use failure rate: 0.2-0.3% - This represents effectiveness when injections are administered precisely every 12 weeks 1, 2, 3
  • Continuation rate: 56% at one year - This is notably the lowest among highly effective reversible contraceptives, meaning nearly half of women discontinue within the first year 1, 4

Clinical Context and Comparative Effectiveness

The 6% typical use failure rate places Depo-Provera in an intermediate effectiveness category, significantly less effective than long-acting reversible contraceptives (LARCs) in real-world use:

  • Nexplanon (implant): 0.05% typical use failure rate - Nearly 100 times more effective than Depo-Provera in typical use 2, 3
  • Mirena (hormonal IUD): 0.2% typical use failure rate - Approximately 30 times more effective than Depo-Provera in typical use 2, 3
  • Combined oral contraceptives: 9% typical use failure rate - Slightly less effective than Depo-Provera 1

The key difference is that LARCs eliminate user adherence issues entirely, whereas Depo-Provera requires women to remember quarterly appointments, and the gap between perfect and typical use reflects missed or delayed injections 2, 3.

Real-World Pregnancy Data

Population-based studies provide additional context on actual failure rates:

  • A Planned Parenthood review found a crude rate of 0.42 pregnancies per 1,000 women per year among Depo-Provera users, though 45% of pregnancies occurred after the injection window had expired 5
  • A New Zealand population study reported only 0.9 pregnancies per 100 woman-years, with contraceptive failure accounting for just 1.6% of discontinuations 6
  • These lower observed rates likely reflect that many "failures" are actually due to missed injections rather than true method failure 5

Critical Timing Requirements

Depo-Provera must be administered every 12 weeks (84 days ± 5 days) to maintain contraceptive effectiveness. 1 The typical use failure rate of 6% primarily reflects pregnancies that occur when women delay or miss their scheduled injections beyond this window 1.

Important Clinical Caveats

Several factors contribute to the gap between perfect and typical use effectiveness:

  • Poor continuation rates driven by menstrual irregularities, weight gain concerns, and bone density warnings lead to discontinuation and subsequent pregnancy risk 4, 6, 7
  • Delayed pregnancy recognition - 46% of pregnancies during Depo-Provera use were diagnosed after the first trimester, and 19% of women received additional injections while already pregnant 5
  • Return to fertility delay of up to 18 months after discontinuation may paradoxically contribute to unintended pregnancies when women stop the method 1

The American College of Obstetricians and Gynecologists emphasizes that pre-injection counseling about menstrual changes significantly improves continuation rates, which directly impacts real-world effectiveness 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Contraception Options with High Efficacy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Contraceptive Efficacy and Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Depo-Provera Limitations and Disadvantages

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Depo Provera. Position paper on clinical use, effectiveness and side effects.

The British journal of family planning, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.